Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico
- 1 July 2017
- journal article
- review article
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 29 (4) , 185-200
Abstract
No abstract availableKeywords
This publication has 198 references indexed in Scilit:
- Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver diseaseHepatology, 2011
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver DiseaseAmerican Journal of Gastroenterology, 2011
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatology, 2009
- Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and WomenJAMA, 2009
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory responseHepatology, 2008
- Effect of 6‐Month Calorie Restriction and Exercise on Serum and Liver Lipids and Markers of Liver FunctionObesity, 2008
- Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary PreventionJAMA, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005